The progress of mRNA cancer vaccine research – Paolo Ascierto’s interview with Century of Italy
Paolo Ascierto, Director of the Department of Melanoma, Cancer Immunotherapy and Development Therapeutics at RCCS National Cancer Institute G. Pascale Foundation, shared a post on LinkedIn:
“In this interview with Century of Italy (Secolo D’Italia), I had the opportunity to discuss the progress of mRNA cancer vaccine research and the significant advancements in oncological immunotherapy.
The results are encouraging and bring us closer to a future where this therapy will become a concrete reality for patients. Our goal is to make the vaccine available within two years – an ambitious milestone, but achievable thanks to teamwork and scientific innovation.
A big thank you to Alice Carrazza for the interview, which you can read here.”
More posts featuring Paolo Ascierto.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023